1	Met	_	NN	_	_	2	NMOD	_	_
2	amplification	_	NN	_	_	0	ROOT	_	_
3	and	_	CC	_	_	2	COORD	_	_
4	tumor	_	NN	_	_	5	NMOD	_	_
5	progression	_	NN	_	_	3	CONJ	_	_
6	in	_	IN	_	_	2	NMOD	_	_
7	Cdkn2a-deficient	_	JJ	_	_	8	NMOD	_	_
8	melanocytes	_	NNS	_	_	6	PMOD	_	_
9	.	_	.	_	_	2	P	_	_
		
1	While	_	IN	_	_	20	VMOD	_	_
2	many	_	JJ	_	_	4	NMOD	_	_
3	genetic	_	JJ	_	_	4	NMOD	_	_
4	alterations	_	NNS	_	_	5	VMOD	_	_
5	have	_	VBP	_	_	1	SUB	_	_
6	been	_	VBN	_	_	5	VC	_	_
7	identified	_	VBN	_	_	6	VC	_	_
8	in	_	IN	_	_	7	VMOD	_	_
9	melanoma	_	NN	_	_	8	PMOD	_	_
10	,	_	,	_	_	20	P	_	_
11	the	_	DT	_	_	14	NMOD	_	_
12	relevant	_	JJ	_	_	14	NMOD	_	_
13	molecular	_	JJ	_	_	14	NMOD	_	_
14	events	_	NNS	_	_	20	VMOD	_	_
15	that	_	WDT	_	_	16	VMOD	_	_
16	contribute	_	VBP	_	_	14	NMOD	_	_
17	to	_	TO	_	_	16	VMOD	_	_
18	disease	_	NN	_	_	19	NMOD	_	_
19	progression	_	NN	_	_	17	PMOD	_	_
20	are	_	VBP	_	_	0	ROOT	_	_
21	poorly	_	RB	_	_	20	VMOD	_	_
22	understood	_	VBN	_	_	20	VC	_	_
23	.	_	.	_	_	20	P	_	_
		
1	Most	_	JJS	_	_	4	NMOD	_	_
2	primary	_	JJ	_	_	4	NMOD	_	_
3	human	_	JJ	_	_	4	NMOD	_	_
4	melanomas	_	NNS	_	_	5	VMOD	_	_
5	exhibit	_	VBP	_	_	0	ROOT	_	_
6	loss	_	NN	_	_	5	VMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	expression	_	NN	_	_	7	PMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	the	_	DT	_	_	12	NMOD	_	_
11	CDKN2A	_	NN	_	_	12	NMOD	_	_
12	locus	_	NN	_	_	9	PMOD	_	_
13	in	_	IN	_	_	8	NMOD	_	_
14	addition	_	NN	_	_	13	PMOD	_	_
15	to	_	TO	_	_	14	NMOD	_	_
16	activation	_	NN	_	_	15	PMOD	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	the	_	DT	_	_	24	NMOD	_	_
19	canonical	_	JJ	_	_	24	NMOD	_	_
20	mitogen-activated	_	JJ	_	_	22	NMOD	_	_
21	protein	_	NN	_	_	22	NMOD	_	_
22	kinase	_	NN	_	_	24	NMOD	_	_
23	signaling	_	NN	_	_	24	NMOD	_	_
24	pathway	_	NN	_	_	17	PMOD	_	_
25	.	_	.	_	_	5	P	_	_
		
1	In	_	IN	_	_	6	VMOD	_	_
2	this	_	DT	_	_	3	NMOD	_	_
3	study	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	we	_	PRP	_	_	6	VMOD	_	_
6	used	_	VBD	_	_	0	ROOT	_	_
7	a	_	DT	_	_	12	NMOD	_	_
8	Cdkn2a-deficient	_	JJ	_	_	12	NMOD	_	_
9	mouse	_	NN	_	_	12	NMOD	_	_
10	melanocyte	_	NN	_	_	12	NMOD	_	_
11	cell	_	NN	_	_	12	NMOD	_	_
12	line	_	NN	_	_	6	VMOD	_	_
13	to	_	TO	_	_	6	VMOD	_	_
14	screen	_	VB	_	_	13	IM	_	_
15	for	_	IN	_	_	14	VMOD	_	_
16	secondary	_	JJ	_	_	18	NMOD	_	_
17	genetic	_	JJ	_	_	18	NMOD	_	_
18	events	_	NNS	_	_	15	PMOD	_	_
19	in	_	IN	_	_	18	NMOD	_	_
20	melanoma	_	NN	_	_	22	NMOD	_	_
21	tumor	_	NN	_	_	22	NMOD	_	_
22	progression	_	NN	_	_	19	PMOD	_	_
23	.	_	.	_	_	6	P	_	_
		
1	Upon	_	IN	_	_	19	VMOD	_	_
2	investigation	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	19	P	_	_
4	intrachromosomal	_	NN	_	_	6	NMOD	_	_
5	gene	_	NN	_	_	6	NMOD	_	_
6	amplification	_	NN	_	_	19	VMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	Met	_	NN	_	_	7	PMOD	_	_
9	,	_	,	_	_	8	P	_	_
10	a	_	DT	_	_	13	NMOD	_	_
11	receptor	_	NN	_	_	13	NMOD	_	_
12	tyrosine	_	NN	_	_	13	NMOD	_	_
13	kinase	_	NN	_	_	8	APPO	_	_
14	implicated	_	VBN	_	_	13	APPO	_	_
15	in	_	IN	_	_	14	VMOD	_	_
16	melanoma	_	NN	_	_	17	NMOD	_	_
17	progression	_	NN	_	_	15	PMOD	_	_
18	,	_	,	_	_	8	P	_	_
19	was	_	VBD	_	_	0	ROOT	_	_
20	identified	_	VBN	_	_	19	VC	_	_
21	in	_	IN	_	_	20	VMOD	_	_
22	Cdkn2a-deficient	_	JJ	_	_	23	NMOD	_	_
23	tumors	_	NNS	_	_	21	PMOD	_	_
24	.	_	.	_	_	19	P	_	_
		
1	RNA	_	NN	_	_	2	NMOD	_	_
2	interference	_	NN	_	_	9	VMOD	_	_
3	targeting	_	VBG	_	_	2	APPO	_	_
4	Met	_	NN	_	_	3	VMOD	_	_
5	in	_	IN	_	_	4	NMOD	_	_
6	these	_	DT	_	_	8	NMOD	_	_
7	tumor	_	NN	_	_	8	NMOD	_	_
8	cells	_	NNS	_	_	5	PMOD	_	_
9	resulted	_	VBD	_	_	0	ROOT	_	_
10	in	_	IN	_	_	9	VMOD	_	_
11	a	_	DT	_	_	13	NMOD	_	_
12	significant	_	JJ	_	_	13	NMOD	_	_
13	delay	_	NN	_	_	10	PMOD	_	_
14	in	_	IN	_	_	13	NMOD	_	_
15	tumor	_	NN	_	_	16	NMOD	_	_
16	growth	_	NN	_	_	14	PMOD	_	_
17	in	_	FW	_	_	16	NMOD	_	_
18	vivo	_	FW	_	_	17	AMOD	_	_
19	compared	_	VBN	_	_	9	VMOD	_	_
20	with	_	IN	_	_	19	VMOD	_	_
21	the	_	DT	_	_	23	NMOD	_	_
22	control	_	JJ	_	_	23	NMOD	_	_
23	cells	_	NNS	_	_	20	PMOD	_	_
24	.	_	.	_	_	9	P	_	_
		
1	MET	_	NN	_	_	2	NMOD	_	_
2	expression	_	NN	_	_	3	VMOD	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	rarely	_	RB	_	_	3	VMOD	_	_
5	detected	_	VBN	_	_	3	VC	_	_
6	in	_	IN	_	_	5	VMOD	_	_
7	primary	_	JJ	_	_	9	NMOD	_	_
8	human	_	JJ	_	_	9	NMOD	_	_
9	melanoma	_	NN	_	_	6	PMOD	_	_
10	but	_	CC	_	_	3	COORD	_	_
11	is	_	VBZ	_	_	10	CONJ	_	_
12	frequently	_	RB	_	_	11	VMOD	_	_
13	observed	_	VBN	_	_	11	VC	_	_
14	in	_	IN	_	_	13	VMOD	_	_
15	metastatic	_	JJ	_	_	16	NMOD	_	_
16	disease	_	NN	_	_	14	PMOD	_	_
17	.	_	.	_	_	3	P	_	_
		
1	This	_	DT	_	_	2	NMOD	_	_
2	study	_	NN	_	_	3	VMOD	_	_
3	validates	_	VBZ	_	_	0	ROOT	_	_
4	a	_	DT	_	_	5	NMOD	_	_
5	role	_	NN	_	_	3	VMOD	_	_
6	for	_	IN	_	_	5	NMOD	_	_
7	Met	_	NN	_	_	8	NMOD	_	_
8	activation	_	NN	_	_	6	PMOD	_	_
9	in	_	IN	_	_	5	NMOD	_	_
10	melanoma	_	NN	_	_	12	NMOD	_	_
11	tumor	_	NN	_	_	12	NMOD	_	_
12	progression	_	NN	_	_	9	PMOD	_	_
13	in	_	IN	_	_	12	NMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	context	_	NN	_	_	13	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	Cdkn2a	_	NN	_	_	18	NMOD	_	_
18	deficiency	_	NN	_	_	16	PMOD	_	_
19	.	_	.	_	_	3	P	_	_
		
